TY -的盟Gaibar玛丽亚盟————劳拉AU - Romero-Lorca,艾丽西亚盟——Fernandez-Santander安娜盟——Novillo Apolonia PY - 2020 DA - 2020/03/07 TI -体细胞突变HER2对目前的治疗模式和影响HER2阳性的乳腺癌SP - 6375956六世- 2020 AB -在一个每四或五例乳腺癌,人类表皮生长因子受体2 ( HER2)基因过表达。这些癌称为her2阳性。HER2过度与咄咄逼人的表型和无病生存和整体比例更低。拉帕替尼,等药物曲妥珠单抗,pertuzumab neratinib,最近afatinib目标HER2表达的放松管制。一些作者认为在HER2体细胞突变,一个角色在抵抗anti-HER2治疗HER2微分调节都观察到病人。最近,ER +肿瘤转移的研究表明,一些HER2基因突变成为内分泌治疗的获得性耐药机制。为了确定可能的生物标志物anti-HER2疗法的疗效,我们这里回顾已知的单核苷酸多态性(snp)的HER2基因中发现HER2阳性乳腺癌患者及其与临床结果之间的关系。体细胞HER2 snp 11日信息被重新编译。七个多态性位于酪氨酸激酶域的区域对比数量低的突变基因在细胞外和跨膜区。her2阳性患者携带S310F S310Y、R678Q D769H,或I767M突变似乎适合使用anti-HER2治疗显示良好的结果,好应对目前的药物治疗。 Carrying the L755S or D769Y mutation could also confer benefits when receiving neratinib or afatinib. By contrast, patients with mutations L755S, V842I, K753I, or D769Y do not seem to benefit from trastuzumab. Resistance to lapatinib has been reported in patients with L755S, V842I, and K753I. These data suggest that exploring HER2 SNPs in each patient could help individualize anti-HER2 therapies. Advances in our understanding of the genetics of the HER2 gene and its relations with the efficacy of anti-HER2 treatments are needed to improve the outcomes of patients with this aggressive breast cancer. SN - 1687-8450 UR - https://doi.org/10.1155/2020/6375956 DO - 10.1155/2020/6375956 JF - Journal of Oncology PB - Hindawi KW - ER -